NeoVista's wet age-related macular degeneration device:
This article was originally published in Clinica
Fremont, California-based NeoVista has CE marked its focal epiretinal brachytherapy device for sale in Europe. The wet age-related macular degeneration (AMD) therapy delivers focused beta radiation - using strontium 90 - to the leaking blood vessels that affect central vision, without causing damage to the surrounding tissues. The company says that preliminary data show it to be safe for both the patient and the physician and may be able to reverse vision loss. NeoVista is currently conducting the final US phase III clinical trial required to gain US approval for the technology.